“Healthy” innovation: putting patients before profits – the HTA perspective

Beate Wieseler
19th European Health Forum Gastein
28 September 2016
Context of benefit assessment

Regulatory decision making

(German) HTA decision making

Assessment criteria
- Mortality
- Morbidity
- HRQoL

Data requirements:
- Full public availability of all study data

Benefit / risk

Added benefit

Pricing

Ensure safe treatment

Enable choice of best treatment
Ensure sustainable health care systems
Results of the current R&D system

Proof of added benefit of new drugs
(N=147)

- Major: 56%
- Considerable: 16%
- Minor: 10%
- Not quantifiable: 7%
- Less benefit: 1%
- No added benefit: 1%

Oncology (N=43)

- Major: 30%
- Considerable: 26%
- Minor: 12%
- Not quantifiable: 2%
- Less benefit: 5%
- No added benefit: 2%

Diabetes (N=11)

- Major: 73%
- Considerable: 18%
- Minor: 0%
- Not quantifiable: 0%
- Less benefit: 0%
- No added benefit: 0%

Psychiatry/Neurology (N=15)

- Major: 87%
- Considerable: 7%
- Minor: 7%
- Not quantifiable: 0%
- Less benefit: 0%
- No added benefit: 0%

28 September 2016
Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

- Im Mediapark 8
- D-50670 Köln
- Telefon +49-221/3 56 85-0
- Telefax +49-221/3 56 85-1
- info@iqwig.de
- www.iqwig.de